208 related articles for article (PubMed ID: 16324386)
21. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
22. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
23. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
24. [Ovarian tumors of low malignant potential (borderline ovarian tumors)].
Luchian AM; Pricop M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):438-45. PubMed ID: 21870737
[TBL] [Abstract][Full Text] [Related]
25. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
26. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.
Ahmed N; Riley C; Rice GE; Quinn MA; Baker MS
J Histochem Cytochem; 2002 Oct; 50(10):1371-80. PubMed ID: 12364570
[TBL] [Abstract][Full Text] [Related]
27. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between cyclooxygenase-2 protein expression, prostaglandins levels and biologic behavior in ovarian carcinoma tissue].
Tang L; Wang M; Ma J
Zhonghua Fu Chan Ke Za Zhi; 2002 Nov; 37(11):687-90. PubMed ID: 12487927
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
30. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.
Klimp AH; Hollema H; Kempinga C; van der Zee AG; de Vries EG; Daemen T
Cancer Res; 2001 Oct; 61(19):7305-9. PubMed ID: 11585770
[TBL] [Abstract][Full Text] [Related]
31. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital of eastern India.
Mondal SK; Banyopadhyay R; Nag DR; Roychowdhury S; Mondal PK; Sinha SK
J Cancer Res Ther; 2011; 7(4):433-7. PubMed ID: 22269405
[TBL] [Abstract][Full Text] [Related]
32. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
34. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
[TBL] [Abstract][Full Text] [Related]
35. Epithelial ovarian tumors in adolescents: a retrospective pathologic study and a critical review of the literature.
Grapsa D; Kairi-Vassilatou E; Kleanthis C; Dastamani C; Fillipidou A; Kondi-Pafiti A
J Pediatr Adolesc Gynecol; 2011 Dec; 24(6):386-8. PubMed ID: 21945630
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
[TBL] [Abstract][Full Text] [Related]
37. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
39. Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.
Kane SV; Bharadwaj R; Tongaonkar HB
Indian J Cancer; 1999 Mar; 36(1):18-31. PubMed ID: 10810551
[TBL] [Abstract][Full Text] [Related]
40. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
